You have 9 free searches left this month | to do more

obinutuzumab

Obinutuzumab is a drug used to treat Chronic Lymphocytic Leukemia, Follicular Lymphoma, Small Lymphocytic Lymphoma, and other conditions. Obinutuzumab is being actively studied in 97 studies and prior, has been studied in 42.

Top SponsorsTop SitesTop Investigators
Hoffmann-La RocheHospital Universitari Vall d'Hebron; Servicio de HematologiaJonathon Cohen
Genentech, Inc.Samsung Medical CenterJoseph Tuscano
National Cancer Institute (NCI)M D Anderson Cancer CenterMatthew S. Davids, MD
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
U
Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma
Recruiting
  • Mantle Cell Lymphoma
  • +2 more
  • Madison, Wisconsin
    University of Wisconsin Carbone Cancer Center
2022-03-07
Mar 7, 2022
K
Venetoclax and Obinutuzumab for Relapsed/Refractory Primary CNS Lymphoma - 2021
Terminated
  • Primary CNS Lymphoma
  • Stuttgart, Baden-Württemberg, Germany
    Klinikum Stuttgart
2022-01-18
Jan 18, 2022
M
Obinutuzumab in Primary FSGS
Recruiting
  • Primary Focal Segmental Glomerulosclerosis
  • Obinutuzumab
  • Rochester, Minnesota
    Mayo Clinic in Rochester
2021-12-13
Dec 13, 2021
N
Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia - 2021
Terminated
Has Results
  • Leukemia
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2022-03-11
Mar 11, 2022
I
To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)
Not yet recruiting
  • Follicular Lymphoma ( FL)
  • Marginal Zone Lymphoma (MZL)
  • (no location specified)
2022-02-07
Feb 7, 2022
M
Obinutuzumab in Primary MN
Not yet recruiting
  • Membranous Nephropathy
  • Obinutuzumab
  • Bergamo, BG, Italy
  • +1 more
2022-03-11
Mar 11, 2022
S
Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients
Active, not recruiting
  • Follicular Lymphoma
  • Basel, Switzerland
  • +5 more
2022-02-24
Feb 24, 2022
U
A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma
Recruiting
  • Follicular Lymphoma
  • Chicago, Illinois
    University of Chicago Medical Center
2021-11-12
Nov 12, 2021
D
Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell Transplantation
Recruiting
  • Graft vs. Host Disease
  • Obinutuzumab
  • Placebo
  • Palo Alto, California
  • +4 more
2022-03-23
Mar 23, 2022
O
Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma - 2021
Completed
Has Results
  • Recurrent Mantle Cell Lymphoma
  • Refractory Mantle Cell Lymphoma
  • Portland, Oregon
    OHSU Knight Cancer Institute
2021-12-10
Dec 10, 2021
M
Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia
Recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
2021-11-18
Nov 18, 2021
N
Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies
Suspended
  • Follicular Lymphoma
  • +4 more
  • Obinutuzumab
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2022-04-07
Apr 7, 2022
D
A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Boston, Massachusetts
  • +3 more
2022-01-03
Jan 3, 2022
F
Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom's Macroglobulinemia
Active, not recruiting
  • Waldenstrom Macroglobulinemia
  • Tours, France
    Project manager
2021-06-28
Jun 28, 2021
P
Efficacy and Safety of Obinutuzumab Preemptive Treatment at the Time of the Molecular Relapse After First Line Immunochemotherapy With Autologous Stem Cell - 2020
Terminated
  • Mantle Cell Lymphoma
  • Obinutuzumab
  • Warszawa, Poland
  • +1 more
2021-12-23
Dec 23, 2021
M
Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma
Active, not recruiting
  • Grade 3a Follicular Lymphoma
  • +9 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-02-09
Feb 9, 2022
D
Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL
Recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • Stamford, Connecticut
  • +4 more
2021-11-22
Nov 22, 2021
M
Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Recruiting
  • Recurrent Chronic Lymphocytic Leukemia
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-02-10
Feb 10, 2022
E
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
Recruiting
  • Grade 1 Follicular Lymphoma
  • +7 more
  • Atlanta, Georgia
    Emory University Hospital/Winship Cancer Institute
2021-12-07
Dec 7, 2021
A
Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL
Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • +2 more
  • Columbus, Ohio
    Research Site
2022-03-11
Mar 11, 2022
H
A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of RO7227166 in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab Administered in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Recruiting
  • Lymphoma, Non-Hodgkin
  • Melbourne, Victoria, Australia
  • +11 more
2022-04-01
Apr 1, 2022
M
Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma
Active, not recruiting
  • Ann Arbor Stage II Grade 1 Follicular Lymphoma
  • +12 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-02-18
Feb 18, 2022
U
Obinutuzumab in Combination With GDP Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma - 2021
Completed
  • Lymphoma, Non-Hodgkin's
  • Obinutuzumab
  • +3 more
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
2021-04-11
Apr 11, 2021
H
A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Recruiting
  • Lymphoma
  • Obinutuzumab
  • +2 more
  • Beijing, China
  • +6 more
2022-03-16
Mar 16, 2022
M
Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia
Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
2022-01-06
Jan 6, 2022